Clinical Trial Update: A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating liposomal doxorubicin (DOXIL/CAELYX) in patients with advanced or refractory solid malignancies, including ovarian cancer. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxil/Caelyx (liposomal doxorubicin)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasms | Phase 1 | Status: COMPLETED